The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Therapeutic aspects of cannabis and cannabinoids
Open accessAbstract
Background: Review commissioned in 1996 by the Department of Health (DOH). Aims: Assess therapeutic profile of cannabis and cannabinoids. Method: Medline search, references supplied by DOH and others, and personal communications. Results and Conclusions: Cannabis and some cannabinoids are effective antiemetics and analgesics and reduce intraocular pressure. There is evidence of symptom relief and improved well-being in selected neurological conditions, AIDS and certain cancers. Cannabinoids may reduce anxiety and improve sleep. Anticonvulsant activity requires clarification. Other properties identified by basic research await evaluation. Standard treatments for many relevant disorders are unsatisfactory. Cannabis is safe in overdose but often produces unwanted effects, typically sedation, intoxication, clumsiness, dizziness, dry mouth, lowered blood pressure or increased heart rate. The discovery of specific receptors and natural ligands may lead to drug developments. Research is needed to optimise dose and route of administration, quantify therapeutic and adverse effects, and examine interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DISEASES OF THE NERVOUS SYSTEM
JELLIFFE, S. E., & WHITE, W. A. (1918) · The American Journal of the Medical Sciences · doi:10.1097/00000441-191803000-00015 · Cited by 1,277
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 568
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
Beal, J. E., Olson, R., Laubenstein, L., Morales, J. O., Bellman, P., Yangco, B., Lefkowitz, L., Plasse, T. F., & Shepard, K. V. (1995) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(94)00117-4 · Cited by 504
Marijuana and medicine: assessing the science base
(1999) · Choice Reviews Online · doi:10.5860/choice.37-2206 · Cited by 410
Pertwee, R. G. (1977) · Neuroscience · doi:10.1016/0306-4522(77)90080-x · Cited by 382
The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378
Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy
Sallan, S. E., Zinberg, N. E., & Frei, E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510162931603 · Cited by 364
The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis
Consroe, P., Musty, R., Rein, J., Tillery, W., & Pertwee, R. (1997) · European Neurology · doi:10.1159/000112901 · Cited by 323
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., & Schram, K. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 320
Cannabinoids as Therapeutic Agents
(2019) · Chapman & Hall/CRC eBooks · doi:10.1201/9780429260667 · Cited by 311
Research works printed but not linked: 9
- Meek C. (1994) Doctors want cannabis prescriptions allowed. BMA News Review, 15 February, p. 15.
- Hall, 1994, The Health and Psychological Consequences of Cannabis
- Pertwee R. G. (1995) Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors: an overview. In Cannabinoid Receptors (ed. Pertwee R. ), pp. 1–34. Harcourt Brace.
- Lane, 1991, Dronabinol and prochlorperazine in combination are better than either agent alone for treatment of chemotherapy-induced nausea and vomiting, Proceedings of the American Society of Clinical Oncologists, 8, 326
- Hepler, 1976, The Pharmacology of Marihuana
- 1988, Cannabis: The Scientific and Medical Evidence (HL Paper 151)
- Ilaria, 1981, Nabilone, a cannabinol derivative, in the treatment of anxiety neuroses, Current Therapeutic Research, 29, 943
- Mechoulam, 1986, Cannabinoids as Therapeutic Agents, 1
- Harris, 1976, The Pharmacology of Marihuana, Vol. 2, 749
Cited by
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
The neurobiology and control of anxious states
Millan, M. J. (2003) · Progress in Neurobiology · doi:10.1016/s0301-0082(03)00087-x · Cited by 965
Iversen, L. (2003) · Brain · doi:10.1093/brain/awg143 · Cited by 732
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Gobbi, G., Bambico, F. R., Mangieri, R., Bortolato, M., Campolongo, P., Solinas, M., Cassano, T., Morgese, M. G., Debonnel, G., Duranti, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509591102 · Cited by 673
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Jiang, W. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25509 · Cited by 527
Han, J., Kesner, P., Metna-Laurent, M., Duan, T., Xu, L., Georges, F., Koehl, M., Abrous, D. N., Mendizabal-Zubiaga, J., Grandes, P., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.037 · Cited by 514
Endocannabinoid system and stress and anxiety responses
VIVEROS, M., MARCO, E., & FILE, S. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.01.029 · Cited by 485
Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
SVIZENSKA, I., DUBOVY, P., & SULCOVA, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.05.010 · Cited by 457
Plant derived substances with anti-cancer activity: from folklore to practice
Fridlender, M., Kapulnik, Y., & Koltai, H. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00799 · Cited by 415
Antidepressant‐like effects of cannabidiol in mice: possible involvement of 5‐HT1Areceptors
Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., & Joca, S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00521.x · Cited by 366
Cannabinoids reveal importance of spike timing coordination in hippocampal function
Robbe, D., Montgomery, S. M., Thome, A., Rueda-Orozco, P. E., McNaughton, B. L., & Buzsaki, G. (2006) · Nature Neuroscience · doi:10.1038/nn1801 · Cited by 333
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
Manzanares, J., Julian, M., & Carrascosa, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906778019527 · Cited by 287
Pergam, S. A., Woodfield, M. C., Lee, C. M., Cheng, G., Baker, K. K., Marquis, S. R., & Fann, J. R. (2017) · Cancer · doi:10.1002/cncr.30879 · Cited by 267
Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana
Bostwick, J. M. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.10.003 · Cited by 261
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal
Scavone, J. L., Sterling, R. C., & Van Bockstaele, E. J. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.034 · Cited by 209
Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Zhu, H.-J., Wang, J.-S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., & DeVane, C. L. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.098541 · Cited by 192
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Wallace, V. C. J., Cottrell, D. F., Brophy, P. J., & Fleetwood-Walker, S. M. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03221.2003 · Cited by 134
Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood
Haney, M., Rabkin, J., Gunderson, E., & Foltin, R. W. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2242-2 · Cited by 126
Nabilone for the Management of Pain
Tsang, C. C., & Giudice, M. G. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1709 · Cited by 73
Degroot, A., & Nomikos, G. G. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03556.x · Cited by 58
Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort
Osborne, A. J., Pearson, J. F., Noble, A. J., Gemmell, N. J., Horwood, L. J., Boden, J. M., Benton, M. C., Macartney-Coxson, D. P., & Kennedy, M. A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0800-3 · Cited by 47
Ballard, M. E., Gallo, D. A., & de Wit, H. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2924-5 · Cited by 32
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7
Metadata
- Authors
- Robson, P.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2001-02
- Volume
- 178
- Issue
- 2
- Pages
- 107-115
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W1965534002
- Cited by
- 265
- References
- 50
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.